Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis

Area of Science:

• Rheumatology and Immunology
• Molecular Biology
• Genomics

Background:

• Elevated C-reactive protein (CRP) is a common indicator for rheumatoid arthritis (RA), but lacks specificity.
• There is a critical need for more reliable biomarkers for early RA detection and predicting treatment response.
• Methotrexate (MTX) is a common RA treatment, but patient response varies, necessitating predictive biomarkers.

Purpose of the Study:

• To identify novel diagnostic biomarkers for early-stage rheumatoid arthritis (RA).
• To discover gene expression profiles that predict therapeutic efficacy of methotrexate (MTX) in RA patients.

Main Methods:

• Utilized microarray analysis on human fibroblast-like synoviocytes (HFLS) and rheumatoid arthritis (RA) phenotype HFLS-RA cells (untreated and MTX-treated).
• Identified differentially expressed genes and mapped them to RA inflammatory pathways to shortlist candidate genes.
• Quantified gene expression profiles and calculated fold change (FC) to assess differential expression.

Main Results:

• Microarray analysis revealed 74 differentially expressed genes, shortlisted to 10 candidates.
• Gene expression of these 10 candidates was significantly induced in HFLS-RA cells compared to HFLS cells.
• MTX treatment downregulated the transcription profiles of these 10 genes in HFLS-RA cells. HSPA6, MMP1, MMP13, and TNFSF10 showed the most significant expression differences.

Conclusions:

• The gene expression profiles of HSPA6, MMP1, MMP13, and TNFSF10 are potential diagnostic biomarkers for RA.
• These gene profiles may serve as predictive biomarkers for MTX therapeutic efficacy in RA patients.
• This study highlights the utility of specific gene expression patterns in advancing RA diagnostics and personalized treatment.